Small Cap Sentinel: A New Day
March 15 2010 - 7:00AM
It has been a very eventful year for SenoRx Inc. (Nasdaq:SENO) as
the company focused on the intersection of women's health and
oncology has seen its stock price rise precipitously and the grey
clouds of a patent lawsuit subside. For SenoRx, it is indeed a new
day.
It is interesting to consider what SenoRx might have
accomplished without the distraction of litigation taxing the
equity, and thus been able to fully focus on a business plan known
for its robust product pipeline and strong distribution
channels.
In 2009 alone, SenoRx was able to roll-out numerous innovative
product developments within the breast cancer arena, offering
health care providers both diagnostic and therapeutic technologies
to better detect and treat breast cancer. Each product offering
simultaneously increased SenoRx's revenue opportunities while
enhancing its reputation in the health care community.
A couple of examples were the next generation of Contura, known
as "Shape Select", a multi-lumen balloon that allows greater
conformity to lumpectomy cavities. Another is "StarchMark", a
unique marker to help control bleeding as well as improve marker
centration for users.
Currently, SenoRx has plans for this year to develop a
second-generation EnCor system, a new targeted model of SenoSonix
for use in a radiology department and a next-generation radiation
therapy product. Market opportunities for a new RFID tag and
accompanying handheld reader for lesion localization are also being
explored. Singularly and collectively these are major product
launch events for SenoRx as they enable them to continue their
rapid growth in breast care and further cement their footprint in
this key market segment at the forefront of the medical device
technology market.
Similarly, it is intriguing to ponder how Wall Street views the
diminished worry related to the infringement lawsuit. A traditional
axiom holds that among the greatest detractions to a stock price is
uncertainty. The former prospect of the uncertain outcome of a
patent lawsuit with one of SenoRx's top competitors certainly
qualifies.
But again, with the favorable December 2009 decision, SenoRx
should now be able to fully turn its energies and resources to what
it has proven all along, what it is indeed now known for, the
betterment of women's breast cancer treatment.
Statements herein may contain forward-looking statements and are
subject to significant risks and uncertainties affecting results.
Small Cap Sentinel is property of Integrity Media Inc. (IMI). IMI
provides no assurance as to the subject company's plans or ability
to effect proposed actions and cannot project capabilities, intent,
resources, or experience. The subject companies haven't always
approved the statements made in this report. This report is neither
a solicitation to buy nor offer to sell securities and is for
information purposes only and shouldn't be used as basis for
investment decisions. IMI isn't an investment advisor, analyst or
licensed broker dealer and this report isn't investment advice. IMI
has been paid thirty-thousand dollars by SenoRx for this report and
other services to be performed over the remainder of the calendar
year. Paid reports constitute a conflict of interest as to IMI's
ability to remain objective in communication regarding subject
companies.
CONTACT: Integrity Media Inc.
Kurt Divich
702-396-1000
Senorx (MM) (NASDAQ:SENO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Senorx (MM) (NASDAQ:SENO)
Historical Stock Chart
From Jul 2023 to Jul 2024